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Abstract
Background: Giant cell arteritis (GCA) is an inflammatory disease of the larger vessels, typically affecting the temporal arteries, 
but involvement of the carotid and thoracic arteries is not uncommon. Serious complications such as blindness can occur if the 
disease is left untreated. Currently, the gold standard test for GCA is a temporal biopsy, but this invasive technique is not without 
risks and frequently inaccurate. We investigate the use of 18-fluoro-desoxyglucose (18F-FDG) positron emission tomography 
(PET) as a new diagnostic means in GCA.
Methods: We performed a literature search in the MEDLINE database for original research articles written in the English 
language that discussed the use of PET in diagnosing GCA. After applying selection criteria, 9 articles were included for literature 
review and 4 of these were incorporated in a meta-analysis.
Results: 18-FDG uptake in the extracranial arteries is correlated to the presence GCA within patients suspected for vasculitis. In 
our meta-analysis we found the following results: sensitivity 85% (95% CI; 74-92%, I2=0.0%), specificity 91% (95% CI; 82-96%, 
I2=31.2%), positive likelihood ratio 7.18 (95% CI; 3.43-15.06, I2 =10.1%) and negative likelihood ratio 0.19 (95% CI; 0.11-0.33, 
I2= 0.0%).
Discussion: 18F-FDG-PET cannot replace temporal artery biopsy at the present time, because of its limited ability to visualise the 
cranial arteries. However, PET may be provide valuable information when extracranial involvement is suspected, specifically in 
biopsy-negative patients who are strongly suspected of having GCA.
Systematic Review
Background
Giant cell arteritis (GCA) is one of the two types of large vessel 
vasculitis, as classified according to the 2012 Revised International 
Chapel Hill Consensus Conference.[1] GCA is the most common 
primary systemic vasculitis in adults and usually occurs in those 
over the age of 50 years. This age criterion distinguishes GCA 
from the other type of large vessel vasculitis, Takayasu’s arteritis, 
a disease phenotypically similar to GCA but most commonly 
occuring in those aged younger than 50 years.[1] 
Histopathologically, however, Takayasu’s arteritis and GCA are 
indistinguishable.[1] GCA typically affects the temporal arteries, 
but involvement of the aorta and its major branches, mainly the 
branches of the carotid and vertebral arteries, is often observed. 
With the increasing use of novel imaging techniques, large vessel 
involvement is more frequently recognized.[2,3]
GCA is the most common primary systemic vasculitis in adults. 
In Europe and North America, the estimated prevalence is 
200 per 100 000 and the incidence is 20–30 per 100 000.[4-8] 
If left undiagnosed, the disease progresses and can result in 
audiovestibular dysfunction, generalised peripheral polyneuro-
pathy, stroke, myocardial infarctions, and blindness.[9-12]
 The clinical presentation varies significantly between cases 
and diagnosing CGA can be difficult, but a variety of diagnostic 
tools are helpful in the diagnosis of GCA. These include 
haemoglobin counts, ESR/CRP, liver biochemistry and, most 
importantly, temporal artery biopsies. Because the latter test 
produces far more specific results than the former three [13], a 
positive temporal artery biopsy is currently regarded as the gold 
standard in the diagnosis of GCA.[14]
 However, this gold standard test is not without its limitations. 
In their 1983 study, Hall and colleagues [15] already found that 
its sensitivity is not ideal (85%). They also remarked that in other, 
similar studies, sensitivity had varied between 67% and 97%. In 
these studies, a diagnosis of GCA was made using other strong 
radiological, pathological or clinical evidence.[15,16] This 
means that the current gold standard test will still leave more than 
1 in every 10 patients undiagnosed. These results appear to hold 
true in more recent research, as a Spanish study [17] conducted 
in 2001 found that 29 of 190 patients with proven GCA had a 
negative initial temporal artery biopsy. 
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Biopsies might be negative because the biopsy missed the 
pathologically inflamed area, or because the GCA has an 
atypical phenotype and does not involve the temporal arteries.
[18] Such extracranial involvement can occur in up to 74% of 
GCA patients.[19]
 The current imperfect gold standard and the serious 
morbidity and mortality that are associated with GCA led us to 
investigate alternative methods of diagnosing the disease. One 
such method is the use of positron emission tomography with 
or without computed tomography (PET or PET-CT) to detect 
large vessel inflammation or extracranial involvement secondary 
to GCA. PET has shown promise in detecting extracranial 
involvement of GCA in previous research.[19-22] A PET scan 
is a non-invasive assessment technique compared to temporal 
artery biopsies. Hemorrhage and facial nerve injury have been 
reported as complications of the biopsy procedure.[23,24] In 
addition, several studies report that PET has proven useful in 
diagnosing patients with fever or inflammation of unknown 
origin [25-27] and patients with large vessel vasculitis.[28-30] 
Therefore, the objective of this review is to determine whether 
PET, with or without an added CT component, is a valuable 
addition to the current diagnostic work-up of GCA. 
Methods
Literature search
We performed a search in the MEDLINE database for articles 
written in the English language that addressed the use of 18-FDG 
PET in the diagnostic process of GCA, up to September 2014. 
The exact MeSH-query we used was the following: 
(“Giant Cell Arteritis/diagnosis”[Majr] OR “Giant Cell Arteritis/ 
radiography”[Majr] OR “Giant Cell Arteritis/radionuclide 
imaging”[Majr]) AND ((“Radionuclide Imaging”[majr]) OR 
(“Positron-Emission Tomography”[Mesh])OR (“Fluorode-
oxyglucose F18/diagnostic use”[Mesh])) AND (“humans”[MeSH 
Terms] AND English[lang]) NOT “Case Reports”[ptyp]
We excluded case reports in our search query, because these do not 
provide systematically conducted clinical research for analysis. 
Three authors screened the abstracts independently for eligibility. 
During this process, a further selection was made based on the 
exclusion of abstract-only articles, non-filtered case reports, 
editorials, comment- and response articles, reviews, and papers 
that did not discuss the use of 18-FDG-PET in the diagnostic 
process of GCA. Consensus was reached in case of disagreement 
between authors during the screening process. Full-text versions 
of the remaining articles were read and their references screened 
for other suitable articles. Papers thus found were included in 
our literature review. Additionally, those articles which provided 
Bayesian numerical data (e.g. numbers of true positives, true 
negatives, false positives and false negatives) relevant for assess-
ment of the diagnostic accuracy of PET for GCA were included 
in a meta-analysis. Papers providing such data in incomplete 
form were included only if backwards calculation of sensitivity 
and specificity were possible. Our last search was performed on 
October 3, 2014. The selection process is shown in figure 1. 
Statistical analysis
Where applicable, we recorded the number of true positives, 
true negatives, false positives and false negatives provided by 
the respective authors, as found by PET-scanning using clinical 
criteria or positive temporal artery biopsies as the gold standard. 
In case the authors provided only part of this data, we reversely 
calculated the remainder of the data manually using Bayesian 
mathematics. This data was subsequently pooled and an 
overall sensitivity and specificity were determined. Additionally, 
an overall negative likelihood ratio (NLR) and positive 
likelihood ratio (PLR) were calculated with a random effects 
model. Between-study heterogeneity was assessed by means of 
an I2-test. Calculations were carried out by MetaDiSc version 
4.1.[31]
Results
Literature review
The primary literature search yielded 37 articles, 9 of which were 
selected for inclusion in our literature review after excluding 
non-suitable articles (figure 1). 
 Walter et al. [32] used a four-category visual grading to 
evaluate 18F-FDG-uptake in a total of 30 PET-scans in patients 
with clinically confirmed GCA or Takayasu’s arteritis. ESR 
(p=0.007) and CRP levels (p=0.005) in patients were found to 
be significantly positively correlated with the score these patients 
were assigned on a visual grading scale used for quantifying 
active inflammation, applied after PET-scanning. High ESR/
CRP levels were also associated with a higher sensitivity of the 
PET-scan for the presence of large-vessel vasculitis compared 
to non-elevated ESR/CRP values (up to a maximum of 96% 
sensitivity at a CRP level of 130). Data analysis showed an 
overall sensitivity of 60% and a specificity of 99.8%. Walter and 
colleagues conclude that high ESR or CRP levels increase the 
sensitivity of PET as a diagnostic tool.
37 articles identified  
through MEDLINE search
9 articles selected for 
inclusion in review
4 articles included in  
statistical analysis
28 articles excluded:
• abstracts
• non-filtered case reports
• editorials
• reviews
•  FDG-PET not used  
diagnostically
• article no longer available
5 articles excluded:
•  Diagnostic accuracy  
not assessed
•  GCA grouped with  
other vasculitides
Figure 1- Data selection procedure of literature review 
and statistical analysis
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Blockmans et al. [33] conducted a study to evaluate the use of 
18F-FDG-PET in GCA and polymyalgia rheumatica (PMR). In 
a cohort of 25 patients with clinical symptoms associated with 
GCA or PMR, a PET-scan of the thoracic, femoral and tibial 
arteries was performed and assessed using a four-category 
scoring system similar to the system used by Walter et al..[32] 
Vascular uptake in thoracic arteries was significantly more 
frequently observed (p<0.0001) in patients with GCA. Uptake in 
the thoracic arteries was associated with a sensitivity of 56% and 
a specificity of 98% for the diagnosis of GCA or PMR. Vascular 
uptake in the legs displayed a sensitivity of 64%, but a specificity 
of 77%. The authors speculate that this might be explained by 
the fact that arteriosclerosis is more frequently observed in the 
lower legs.
 These authors subsequently set up another study [34] to 
assess 18F-FDG uptake in different parts of the vascular system 
and the larger joints at diagnosis and after three and six months of 
corticosteroid therapy. 35 patients with proven GCA underwent 
a PET-scan, which was scored at seven different vascular 
regions using the same scoring system as applied in their previous 
research. This resulted in a so-called total vascular score (TVS) 
ranging from 0 (no regions involved) to 21 (all regions involved). 
At baseline 29 out of 35 patients showed vascular uptake, most 
frequently (74%) in the subclavian arteries. In contrast with 
the aforementioned research by Walter et al. [32], patients 
with vascular 18F-FDG uptake had a significantly lower ESR 
(p=0.039) compared to those without vascular uptake in this 
study. After three months of corticosteroid therapy, mean TVS 
dropped to 2.4 ± 3.5 compared to baseline (p<0.0005) in 14 
out of 22 patients who underwent a second PET-scan. After six 
months there was no further significant decrease in mean TVS 
in the 8 patients who still showed 18F-FDG uptake at this point. 
TVS did not differ significantly between patients who did and 
did not relapse.
 In line with the results of the study conducted by Walter et 
al. [32], Hooisma et al. [35] found that an elevated ESR was a 
statistically significant positive predictor for a positive 18F-
FDG-PET-scan in cases of confirmed large vessel vasculitis. 
Additionally, the presence of arthralgia was determined to be a 
statistically significant negative predictor of a positive 18F-FDG-
PET-scan. However, because these predictive effects were very 
weak, Hooisma et al. concluded that these parameters would be 
of little clinical relevance. 
 18F-FDG-PET was not found to be a sensitive diagnostic 
tool by Brodmann et al. [36], who hypothesized that like 
duplex ultrasonography, 18F-FDG-PET would be able to detect 
inflammation of small vessels such as the temporal arteries. 
However, 18F-FDG-PET was unable to detect inflammation in 
17 patients with GCA which only involved the temporal arteries, 
as confirmed by ultrasound. It should be noted that in accordance 
with the results found using ultrasound, PET did detect 
inflammation of the large vessels in all of the remaining 5 
patients, who only had extracranial manifestations of GCA. 
 Hautzel et al. [21] investigated the degree of 18F-FDG 
uptake in the thoracic aorta compared to uptake in the liver, which 
invariably shows homogenous uptake, as a reference organ. 
They quantified the maximal standardised uptake value 
(SUVmax) in predetermined regions of interest (ROI) in both of 
these organs. Subsequently, a cut-off ratio between these organs 
associated with an optimal sensitivity and specificity of the PET-
scan was determined using a receiver operating characteristic 
(ROC). The study involved a cohort of 18 GCA patients and two 
control groups. The participants in the first control group were 
age- and sex-matched patients who underwent a PET-scan for 
oncological reasons but had no history of malignant mediastinal, 
pulmonary or liver processes; the second control group contained 
age- and sex matched participants with at least one elevated liver 
enzyme value. Other inclusion criteria in this group were identical 
to those for the other control group. An optimal cut-off value was 
identified in a comparison between the GCA group and the first 
control group, corresponding with a sensitivity of 88.9% and a 
specificity of 95.1%. Applying this cut-off ratio to the control 
group with elevated liver enzymes revealed a specificity of 
95.6%. The authors did not provide a sensitivity in this study.
 Like Hautzel et al. [21], Prieto-Gonzalez et al. [19] determined 
sensitivity and specificity cut-off values for vascular inflammation 
as seen on PET/CT. A total of 32 patients were included, of whom 
17 had used corticosteroids for a maximum of three days prior 
to scanning. The control group was comprised of 20 patients 
undergoing PET-scans for oncologic reasons. ROIs for 18F-FDG 
uptake were four aortic segments and their loco-regional 
tributaries, all normalised to liver 18F-FDG uptake, and 
SUVmax was determined quantitatively at each of these ROIs. 
SUVmax at every ROI was significantly higher in GCA patients 
compared to controls. The optimal cut-off value (1.89) provided 
a sensitivity of 80% and a specificity of 79%. Patients with 
cranial symptoms presented significantly higher values of 
maximal and mean SUVmax than patients lacking cranial 
manifestations. In agreement with the studies by Hooisma et al. 
[35] and Walter et al. [32], mean SUVmax correlated with CRP 
levels.
 Besson et al. [20] attempted to identify a new semi-quantitative 
standard for assessing the presence of aortic wall inflammation 
in GCA on 18F-FDG-PET-scans. The study included 11 
patients with biopsy-proven GCA, 8 of whom were undergoing 
corticosteroid therapy, and 11 controls. ROIs investigated 
included the ascending aorta, aortic arch and descending 
thoracic aorta. In these regions the SUVmax of 18F-FDG was 
determined semi-quantitatively and normalised to either lung, 
liver or venous blood pool uptake. The aortic to blood pool 
uptake ratio was found to be the most discriminative between 
the two cohorts. When applied to the aortic arch this method 
provided the best diagnostic performance, providing a sensitivity 
and specificity of 82% and 91%, respectively. CRP levels were 
found to correlate with the amount of uptake of the ascending 
aorta in the GCA group, in consonance with research by Walter, 
Hooisma and Hautzel and their respective colleagues.[21,32,35]
 In a cohort including a total of 13 patients with GCA (n=10) 
or Takayasu’s arteritis (n=3), stratified by age, Henes et al. [22] 
found increased SUVmax of 18F-FDG in the ascending and 
descending aorta and supra-aortic branches in 9 out of 10 GCA 
patients. The one patient who did not have increased SUVmax 
was receiving steroid therapy when the PET-scan was performed. 
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However, 5 other patients in this group were also on steroid 
therapy during the PET-procedure. No patients in the control 
group, composed of 8 oncologic patients, showed pathological 
18F-FDG uptake. By means of our own calculations, we 
determined the sensitivity and specificity to be 90% and 100%, 
respectively.
Meta-analysis
Of the 9 articles selected for literature review, 4 were included 
in the statistical analysis. The remaining articles were excluded 
from analysis because they did not assess the diagnostic accuracy 
of PET in GCA in terms of specificity and sensitivity (Blockmans 
et al. (2006), Hooisma et al.), only compared the efficacy of PET 
with the efficacy of another diagnostic technique (Brodmann et 
al.), or analysed a heterogeneous cohort of patients with different 
types of vasculitis as opposed to GCA only, thus confounding 
the statistical data. (Blockmans et al. (2000), Walter et al.). The 
characteristics of the studies included in the meta-analysis are 
presented in table 1. The outcome of the meta-analysis is presented 
in figures 2 through 5.  Overall sensitivity was determined to 
be 85% (95% CI; 74-92%, I2=0.0%), overall specificity was 
determined to be 91% (95% CI; 82-96%, I2=31.2%), positive 
likelihood ratio was determined to be 7.18 (95% CI; 3.43-15.06, 
I2 =10.1%) and negative likelihood ratio was determined to be 
0.19 (95% CI; 0.11-0.33, I2= 0.0%).
Discussion
At 85% sensitivity and 91% specificity, our own analysis 
confirms that PET is an accurate diagnostic tool for GCA. 
Although the resolution of PET has improved in recent years, 
visualisation of the temporal arteries remains very difficult 
because of the high uptake of 18F-FDG in the brain and the 
small size of the cranial vessels.[36,37] This limitation was also 
found by Brodmann et al. [36], who found that PET was unable 
to detect temporal inflammation but flawlessly identified 
extracranial involvement. 
TP = true positives, FP = false positives, TN = true negatives, FN = false negatives, CI = confidence interval, 
LR = likelihood ratio, SUVmax  = maximum standardised uptake value
Table 1 - Characteristics of studies included in meta-analysis.
  
  
 
 
  
  
 
  
  
 
 
 
  
  
 
 
 
Year
2014
2014
2008
2008
Design
Prospective, 
case-control
Retrospective, 
case-control
Retrospective
Retrospective, 
case-control
PET-scoring  
system
Mean of four 
SUVmax-values 
in four different 
aortic segments
SUVmax-ratio  
artery/liver, 
artery/lung and 
artery/venous 
blood pool
Maximum of six 
SUVmax-values 
measured in six 
arterial locations
SUVmax-ratio 
aorta/liver
TP  
26
9
9
16
FP  
4
1
0
2
TN  
16
10
8
34
FN  
6
2
1
2
Sensitivity 
(95% CI)
0.81 
(0.64-0.93)
0.82 
(0.48-0.98)
0.90 
(0.55-1.00)
0.89 
(0.65-0.99)
Specificity 
(95% CI)
0.80  
(0.56-0.94)
0.91
(0.59-1.00)
1.00 
(0.63-1.00)
0.94
(0.81-0.99)
Positive Likelihood 
Ration (95% CI)
4.06 
(1.66 - 9.91)
9.00 
(1.36-59.54)
15.55 
(1.04-232.22)
16.00 
(4.12 - 62.14)
Nagative Likelihood 
Ration (95% CI)
0.23 
(0.11 - 0.50)
0.20 
(0.06-0.71)
0.14 
(0.03-0.64)
0.12 
(0.03-0.44)
Study
Prieto- 
Gonzalez 
et al.
Besson et al.
Henes et al.
Hautzel et al.
Figure 2 - Sensitivity Forest Plot. CI = confidence interval
Figure 3 - Specificity Forest Plot. CI = confidence interval
Figure 4 - Positive Likelihood Ratio (LR) Forest Plot. CI = confidence interval
Figure 5 - Negative Likelihood Ratio (LR) Forest Plot. CI = confidence interval
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 The sensitivity of the biopsy procedure has been reported to 
vary between 67% and 97% (the most common value appearing 
to be around 80-85%)[15-17] but its specificity is often not 
reported. The sensitivity we found in our meta-analysis for 
PET appears almost identical. Because of the aforementioned 
difficulties in visualising the temporal arteries with PET, we do not 
recommend replacing temporal artery biopsies with PET as the 
first diagnostic modality of choice. However, PET might be 
very well suited to demonstrate GCA in patients with a negative 
biopsy but suspected extracranial involvement. PET could 
potentially reach even higher sensitivity and specificity in these 
cases because its limited ability to visualise the cranial vessels 
would be taken out of the equation.
 Several issues arise in the interpretation of our meta-analysis 
and the literature we base our recommendation on. First of all, 
no standard protocol for the scoring of PET scans currently 
exists. Several authors have attempted to design a novel scoring 
system in their research. Hautzel et al. [21] proposed the use of 
a semi-quantitative scoring system based on the ratio between 
the SUVmax measured in the aorta and the liver. However, in 
a head-to-head comparison between different semi-quantitative 
scoring systems by Besson et al. [20], the aorta to liver ratio 
was outperformed by the aortic to venous blood pool SUVmax 
ratio. The latter study was methodically superior (but used a 
significantly smaller cohort) because all patients had biopsy-
proven GCA, versus only clinical suspicion in the study by 
Hautzel et al. [21], and a carefully selected control group. For 
further research into the diagnostic performance of PET in 
GCA, we suggest the adoption of a semi-quantitative scoring 
system as opposed to a quantitative scoring system, because a 
semi-quantitative system generally achieves lower intra- and 
inter-observer variability.[38] We recommend the use of the aortic 
to venous blood pool SUVmax ratio using a cut-off value of 1.53, as 
proposed by Besson et al. [20], in order to achieve an optimal 
sensitivity and specificity.
 Several studies included in our review reported difficulties 
in distinguishing atherosclerosis from vasculitis on PET imaging. 
Atherosclerosis can produce an image similar to vasculitis, 
because increased macrophage metabolism in this disease process 
increases 18F-FDG uptake in the vessel walls. CT provides a 
solution in dealing with this difficulty, even without the use of 
intravenous contrast (which could introduce attenuation errors). 
Dunphy et al. [39] found that calcification found on CT and 
18F-FDG uptake rarely occur simultaneously within a vessel. 
This provides further rationale for the use of joint PET-CT as a 
diagnostic tool for GCA in future research.
Another problem with much of the pre-existing research in this 
field is that GCA is diagnosed inconsistently, based on either 
clinical criteria, a positive temporal artery biopsy or both. 
Because GCA shows significant clinical overlap with Takayasu’s 
arteritis and PMR, arbitrary stratification of patients in one of 
these groups is to some degree unavoidable. However, we argue 
that further research would significantly benefit from selection of 
patients with consistently defined GCA. As positive biopsies are 
currently the most accurate test, disregarding PET, we propose 
the exclusive selection of patients with positive temporal artery 
biopsies who fulfil the ACR-criteria for GCA in future research. 
These ACR-criteria are displayed in table 2.[40] 
As a direct consequence of the overlap between GCA and other 
rheumatic diseases, these disease entities are often pooled in 
analyses investigating the efficacy of PET in large vessel 
vasculitis. In our opinion, a disease-specific targeted approach is 
more desirable because it allows for the design of more accurate 
diagnostic protocols. In order to make our meta-analysis as 
accurate as possible, we excluded studies with heterogeneous 
cohorts, i.e. cohorts consisting of patients with multiple types 
of vasculitis. By doing so, we achieved consistently low 
heterogeneity in our analysis. With increasing understanding of 
the underlying mechanisms and pathology of these diseases, we 
expect more specific research to be available in the near future.
 Another point of note is that a considerable number of 
studies include patients who receive corticosteroid therapy 
during their participation in the study. As demonstrated by 
Walter et al. [32], the sensitivity and specificity of PET directly 
correlate with the degree of active inflammation (ESR/CRP) 
in a patient, with higher accuracy achieved at more active 
inflammation. Therefore, in clinical practice, PET might reach 
higher sensitivity because patients not yet on treatment will have 
highly active inflammation.
 Furthermore, many studies include only small cohort of 
patients, contain poorly matched or absent control groups and 
are retrospective in design. The consequence of such a design is 
that ideally only patients who have positive biopsies are studied. 
Whether there is a difference between the biopsy positive and 
negative GCA patients in terms of the development of 
extracranial manifestations is unknown and difficult to 
investigate. Future research would benefit from larger 
prospective, randomised trials with accurately matched controls. 
 With continuing improvement in radiation dosage, image 
quality and scan time, we expect the sensitivity and specificity 
of PET to rise even further in the nearby future. A breakthrough 
in medical imaging was the introduction of the hybrid PET-CT 
scan. An important disadvantage of PET-scans is that anatomical 
landmarks are very difficult or impossible to recognise. The joint 
use of PET and CT can overcome this obstacle, but CT examination 
can also be used for correction of attenuation on PET images. 
PET-CT is commonly used in oncology, especially in staging 
lung cancer and lymphomas.[41,42] Hybrid PET-CT could 
potentially provide higher diagnostic accuracy that PET alone in 
the diagnosis of GCA. However, using both imaging techniques 
could lead to a significant increase in radiation dose. Research is 
currently being undertaken on how to counteract this disadvantage. 
Rodríguez-Vigil et al. have reported that the use of low-dose CT 
is possible without compromising image quality.[43]
A patient is considered to have GCA if three of these five criteria are met.
Table 2 - 1990 ACR criteria for the diagnosis of GCA.
 
 
 
 
 
1. Age at onset 50 years or more
2. Newly developed (localized) headache
3. Tenderness of temporal artery or decreased pulse
4. ESR greater than or equal to 50 mm/hr
5. Temporal artery biopsy showing vasculitis
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Conclusion
 After consideration of the results of our literature review and 
meta-analysis, we conclude that PET cannot replace temporal 
artery biopsy as a diagnostic modality in GCA at the present time. 
However, when considering GCA in patients with a negative 
biopsy, PET may provide a valuable addition because of its 
ability to visualise extracranial involvement. In our meta-analysis, 
we found that PET has a sensitivity of 85%, a specificity 
of 91%, a positive likelihood ratio of 7.18 and a negative 
likelihood ratio of 0.19 for diagnosing GCA. These values will 
most likely not be directly applicable in clinical situations, 
because the exact accuracy of this diagnostic modality will vary 
with the circumstances in which it is used. PET will achieve a 
higher accuracy in patients with highly active inflammation (high 
ESR/CRP levels) and extensive extracranial inflammation, but 
lower accuracy in those patients who receive immunosuppressive 
treatment (such as corticosteroids). The diagnostic accuracy 
of PET could be improved further by the development of 
standardised scoring systems and the use of joint PET-CT. 
However, our meta-analysis proves that when used in the right 
circumstances, PET is a very accurate diagnostic modality when 
considering GCA in clinical practice.
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